Neoantigen cancer vaccines:a new star on the horizon

作     者：Xiaoling Li Jian You Liping Hong Weijiang Liu Peng Guo Xishan Hao Xiaoling Li;Jian You;Liping Hong;Weijiang Liu;Peng Guo;Xishan Hao

作者机构：Cell Biotechnology LaboratoryTianjin Cancer Hospital Airport HospitalTianjin 300308China National Clinical Research Center for CancerTianjin 300060China Haihe Laboratory of Synthetic BiologyTianjin 300090China Department of Thoracic OncologyTianjin Cancer Hospital Airport HospitalTianjin 300308China Department of Thoracic Oncology SurgeryTianjin Medical University Cancer Institute&HospitalTianjin 300060China Tianjin Medical University Cancer Institute&HospitalTianjin 300060China 

出 版 物：《Cancer Biology & Medicine》 (癌症生物学与医学（英文版）)

年 卷 期：2024年第21卷第4期

页      面：274-311页

核心收录：

学科分类：1002[医学-临床医学] 1001[医学-基础医学(可授医学、理学学位)] 100102[医学-免疫学] 10[医学] 

基　　金：supported by grants from the National Clinical Research Center Cancer Fund the Haihe Laboratory of Synthetic Biology(22HHSWSS00004) 

主　　题：Immunotherapy neoantigen cancer vaccine solid tumors high-throughput sequencing bioinformatics PDOs AI HLA TCR 

摘      要：Immunotherapy represents a promising strategy for cancer treatment that utilizes immune cells or drugs to activate the patient s own immune system and eliminate cancer *** of the most exciting advances within this field is the targeting of neoantigens,which are peptides derived from non-synonymous somatic mutations that are found exclusively within cancer cells and absent in normal *** neoantigen-based therapeutic vaccines have not received approval for standard cancer treatment,early clinical trials have yielded encouraging outcomes as standalone monotherapy or when combined with checkpoint *** made in high-throughput sequencing and bioinformatics have greatly facilitated the precise and efficient identification of ***,personalized neoantigen-based vaccines tailored to each patient have been developed that are capable of eliciting a robust and long-lasting immune response which effectively eliminates tumors and prevents *** review provides a concise overview consolidating the latest clinical advances in neoantigen-based therapeutic vaccines,and also discusses challenges and future perspectives for this innovative approach,particularly emphasizing the potential of neoantigen-based therapeutic vaccines to enhance clinical efficacy against advanced solid tumors.